The DOI matches its Crossref record; 99 of the 102 references it cites were found in a registry or an index.
Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management
Open accessAbstract
Hereditary optic neuropathies result from defects in the human genome, both nuclear and mitochondrial. The two main and most recognised phenotypes are dominant optic atrophy and Leber hereditary optic neuropathy. Advances in modern molecular diagnosis have expanded our knowledge of genotypes and phenotypes of inherited disorders that affect the optic nerve, either alone or in combination, with various forms of neurological and systemic degeneration. A unifying feature in the pathophysiology of these disorders appears to involve mitochondrial dysfunction, suggesting that the retinal ganglion cells and their axons are especially susceptible to perturbations in mitochondrial homoeostasis. As we better understand the pathogenesis behind these genetic diseases, aetiologically targeted therapies are emerging and entering into clinical trials, including treatments aimed at halting the cascade of neurodegeneration, replacing or editing the defective genes or their protein products, and potentially regenerating damaged optic nerves, as well as preventing generational disease transmission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LHON classically manifests as acute to sub-acute, bilateral, painless central vision loss, often with sequential onset.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [2]
In the citing paper
“The m.11778G>A mutation causes a severe clinical form of LHON, with multiple natural history studies in MT-ND4 LHON patients confirming rare and poor recovery, although younger age at onset, especially onset at less than 12 years, portends a relatively better visual prognosis.2,3,6”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [2]
In the citing paper
“There is a male predominance of about 80% and patients typically become affected between age 15 and 35 years.2,3”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [2]
Citations
Cites
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786
Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease
Gorman, G. S., Schaefer, A. M., Ng, Y., Gomez, N., Blakely, E. L., Alston, C. L., Feeney, C., Horvath, R., Yu‐Wai‐Man, P., Chinnery, P. F., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24362 · Cited by 936
Self-citationMitochondrial dysfunction as a cause of optic neuropathies
Carelli, V., Ross-Cisneros, F. N., & Sadun, A. A. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.10.003 · Cited by 839
Self-citationCasari, G., De Fusco, M., Ciarmatori, S., Zeviani, M., Mora, M., Fernandez, P., De Michele, G., Filla, A., Cocozza, S., Marconi, R., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81203-9 · Cited by 830
A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing
Mok, B. Y., de Moraes, M. H., Zeng, J., Bosch, D. E., Kotrys, A. V., Raguram, A., Hsu, F., Radey, M. C., Peterson, S. B., Mootha, V. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2477-4 · Cited by 718
Disturbed mitochondrial dynamics and neurodegenerative disorders
Burté, F., Carelli, V., Chinnery, P. F., & Yu-Wai-Man, P. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.228 · Cited by 660
Self-citationMitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Self-citationA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Self-citationRiordan-Eva, P., Sanders, M. D., Govan, G. G., Sweeney, M. G., Costa, J. D., & Harding, A. E. (1995) · Brain · doi:10.1093/brain/118.2.319 · Cited by 490
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Man, P. Y. W., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 483
Self-citation
Research works printed but not linked: 6
- Liu, 2021, Low vision rehabilitation in improving the quality of life for patients with impaired vision: a systematic review and meta-analysis of 52 randomized clinical trials, Medicine (Baltimore), 100
- Klopstock, 2022, Long-term efficacy and safety of idebenone in patients with LHON in the subacute/dynamic phase: results from the LEROS study. Presented at the 2022 Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO), Invest Ophthalmol Vis Sci, 63, 433
- Lloria, 2022, Long-term efficacy and safety of idebenone in patients with LHON in the chronic phase: results from the LEROS study. Presented at the 2022 Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO), Invest Ophthalmol Vis Sci, 63
- Xiao, 2020, First China international gene therapy study in Leber's hereditary optic neuropathy, Mol Ther, 28, 558
- Karanjia, 2019, Elamipretide (MTP-131) topical ophthalmic solution for the treatment of Leber's hereditary optic neuropathy. Presented at the 2019 ARVO Annual Meeting, Invest Ophthalmol Vis Sci, 60
- Harvey, 2021, Induced pluripotent stem cells for inherited optic neuropathies—disease modelling and therapeutic development, J Neuroophthalmol
Cited by
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Bennett, J. L., Costello, F., Chen, J. J., Petzold, A., Biousse, V., Newman, N. J., & Galetta, S. L. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00187-9 · Cited by 226
Self-citationImaging of the optic nerve: technological advances and future prospects
Biousse, V., Danesh-Meyer, H. V., Saindane, A. M., Lamirel, C., & Newman, N. J. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00173-9 · Cited by 134
Self-citationRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
“especially onset at less than 12 years, portends a relatively better visual prognosis.(2,3,6)”
Self-citationYu‐Wai‐Man, P., Carelli, V., Newman, N. J., Silva, M. J., Linden, A., Stavern, G. V., Szaflik, J. P., Banik, R., Lubiński, W., Pemp, B., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101437 · Cited by 70
Self-citationMitochondrial optic neuropathies
Carelli, V., Morgia, C. L., & Yu‐Wai‐Man, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821751-1.00010-5 · Cited by 55
Self-citation
Metadata
- Authors
- Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V.
- Affiliations
- Emory University (US)
- Corresponding author
- Newman, Nancy J
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 22
- Issue
- 2
- Pages
- 172-188
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4296901011
- Cited by
- 97
- References
- 102
- Citations by year
- 2026: 23 · 2025: 25 · 2024: 30 · 2023: 12
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 168 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Neurology (acceptedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Institute for Health and Care Research (G1002570)
- UCL Institute of Ophthalmology, University College London
- Fondazione Telethon (GGP20115)
- Ministero della Salute (RF-2018-12366703)
- Medical Research Council
- National Eye Institute (P30-EY06360)
- Moorfields Eye Hospital NHS Foundation Trust
- Research to Prevent Blindness (NIHR301696)
- Moorfields Eye Charity (GR001376)
- Fight for Sight
- NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
- Manchester Biomedical Research Centre
- Ministero dell’Istruzione, dell’Università e della Ricerca (20172T2MHH)
- National Institutes of Health
- Isaac Newton Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- hereditary optic neuropathy, Leber's hereditary optic neuropathy, autosomal dominant optic atrophy, mitochondrial dysfunction, retinal ganglion cells, genotype-phenotype correlation, molecular diagnosis, pathogenesis, gene therapy, genome editing, neurodegeneration, optic nerve regeneration, disease transmission prevention
- MeSH terms
- DNA, Mitochondrial, Humans, Mitochondria, Optic Nerve, Optic Nerve Diseases, Optic Atrophy, Autosomal Dominant, Optic Atrophy, Hereditary, Leber
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. https://app.cochat.ai/papers/10.1016/s1474-4422(22)00174-0
- The paper
- Newman, N. J., Yu-Wai-Man, P., Biousse, V., & Carelli, V. (2023). Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(22)00174-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.